Questions and answers about data integrity FDA published April 14 as draft guidance could go a long way toward helping drug manufacturers avoid the type of import alerts and warning letters that in recent years have dominated the agency's drug good manufacturing practices enforcement activities.
The percentage of firms placed on drug GMP import alert that have data integrity issues steadily has risen from zero to 56% over the past five years, according to data...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?